Concepedia

Author

Mimi L. Quan

Bristol-Myers Squibb (United States)ORCID

Also Known As

M. L. C. QUAN, M. L. QUAN, M. Quan, M.L. Quan, MengJie Quan, Mimi L Quan, Mimi L. C. Quan, Mimi L. Quan, Mimi Quan, Minbo Quan

63

Publications

2K

Citations

27

H-Index

39

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Wilmington UniversityDuPont (United States)Bristol-Myers Squibb (Germany)Experimental Station
ML

About

Mimi L. Quan is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

24

897

2

Natural Sciences

14

15

558

3

Arts

1

1

185

4

Engineering

1

1

16

5

Applied Physics

1

1

14

Mimi L. Quan

×

40

Publications

1.8K

Citations

25

H-Index

YearCitations

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Mimi L. Quan, Patrick Y. S. Lam, Qi Han,

Journal of Medicinal Chemistry

2004

188

Constrictive binding of large guests by a hemicarcerand containing four portals

Mimi L. Quan, Donald J. Cram

Journal of the American Chemical Society

1991

185

Discovery of 1-[3-(Aminomethyl)phenyl]-<i>N</i>-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1<i>H</i>-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Shuaige Wang,

Journal of Medicinal Chemistry

2001

172

Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1

Mimi L. Quan, Ann Y. Liauw, Christopher D. Ellis,

Journal of Medicinal Chemistry

1999

80

Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 2

Mimi L. Quan, Christopher D. Ellis, Ann Y. Liauw,

Journal of Medicinal Chemistry

1999

77

Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors

Mimi L. Quan, Pancras C. Wong, Cailan Wang,

Journal of Medicinal Chemistry

2014

76

Nonpeptide Factor Xa Inhibitors: I. Studies with SF303 and SK549, a New Class of Potent Antithrombotics

Pancras C. Wong, Mimi L. Quan, Earl J. Crain,

Journal of Pharmacology and Experimental Therapeutics

2000

71

1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa

Donald Pinto, Michael J. Orwat, Mimi L. Quan,

Bioorganic & Medicinal Chemistry Letters

2006

63

Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs

Donglu Zhang, Nirmala Raghavan, Shiang-Yuan Chen,

Drug Metabolism and Disposition

2007

56

Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)

Donald Pinto, Michael J. Orwat, Leon M. Smith,

Journal of Medicinal Chemistry

2017

50

Page 1